Unit of Endocrinology, Department of Internal Medicine, Misericordia Hospital, 58100, Grosseto, Italy.
Unit of Nuclear Medicine, Misericordia Hospital, Grosseto, Italy.
J Endocrinol Invest. 2022 May;45(5):1079-1083. doi: 10.1007/s40618-021-01725-y. Epub 2022 Jan 16.
It is well established that thyroiditis and other thyroid disorders can be induced by COVID-19 infection, but there is limited information about the autoimmune/inflammatory syndrome induced by adjuvants (ASIA) after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. We report two cases of thyrotoxicosis following SARS-CoV-2 vaccine.
Two young health care peoples (wife and husband) received a first dose of SARS-CoV-2 vaccine, and few weeks later developed clinical manifestations of thyroid hyperactivity, with increased thyroid hormone levels on thyroid function tests, suppressed thyroid-stimulating hormone and negative antithyroid antibodies, despite being healthy before vaccination. They were diagnosed at the 4th week after first dose of SARS-Cov-2 vaccine as silent thyroiditis and followed without treatment, since their symptoms were not severe. At the 6th week, the patients became wholly asymptomatic and their thyroid function returned to normal.
Thyrotoxicosis can occur after SARS-CoV-2 vaccination probably related to silent thyroiditis.
众所周知,甲状腺炎和其他甲状腺疾病可由 COVID-19 感染引起,但关于严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)疫苗接种后佐剂引起的自身免疫/炎症综合征(ASIA)的信息有限。我们报告了两例 SARS-CoV-2 疫苗接种后发生的甲状腺功能亢进症。
两名年轻的医护人员(夫妻)接种了第一剂 SARS-CoV-2 疫苗,几周后出现甲状腺功能亢进的临床症状,甲状腺功能检查显示甲状腺激素水平升高,甲状腺刺激激素抑制,抗甲状腺抗体阴性,尽管接种疫苗前身体健康。他们在接种 SARS-CoV-2 疫苗第一剂后第 4 周被诊断为亚急性甲状腺炎,未予治疗,因为症状不严重。第 6 周时,患者完全无症状,甲状腺功能恢复正常。
甲状腺功能亢进症可能发生在 SARS-CoV-2 疫苗接种后,可能与亚急性甲状腺炎有关。